Evidence map›Paper›PMID 35018381›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose.

Francis Mwimanzi, Hope R Lapointe, Peter K Cheung, Yurou Sang, Fatima Yaseen, Gisele Umviligihozo, Rebecca Kalikawe, Sneha Datwani, F Harrison Omondi, Laura Burns and 20 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 1 country.

Francis MwimanziFaculty of Health Sciences, Simon Fraser University, Canada.
Hope R LapointeBritish Columbia Centre for Excellence in HIV/AIDS, Canada.
Peter K CheungFaculty of Health Sciences, Simon Fraser University, Canada.
Yurou SangFaculty of Health Sciences, Simon Fraser University, Canada.
Fatima YaseenFaculty of Health Sciences, Simon Fraser University, Canada.
Gisele UmviligihozoFaculty of Health Sciences, Simon Fraser University, Canada.
Rebecca KalikaweFaculty of Health Sciences, Simon Fraser University, Canada.
Sneha DatwaniFaculty of Health Sciences, Simon Fraser University, Canada.
F Harrison OmondiFaculty of Health Sciences, Simon Fraser University, Canada.
Laura BurnsDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Landon YoungDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Victor LeungDepartment of Medicine, University of British Columbia, Canada.
Olga AgafiteiFaculty of Health Sciences, Simon Fraser University, Canada.
Siobhan EnnisFaculty of Health Sciences, Simon Fraser University, Canada.
Winnie DongBritish Columbia Centre for Excellence in HIV/AIDS, Canada.
Simran BasraFaculty of Health Sciences, Simon Fraser University, Canada.
Li Yi LimFaculty of Health Sciences, Simon Fraser University, Canada.
Kurtis NgFaculty of Health Sciences, Simon Fraser University, Canada.
Ralph PantophletFaculty of Health Sciences, Simon Fraser University, Canada.
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Canada.
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Canada.
Natalie PrystajeckyDepartment of Pathology and Laboratory Medicine, University of British Columbia, Canada.
Christopher F LoweDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Mari L DeMarcoDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Daniel T HolmesDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Janet SimonsDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Masahiro NiikuraFaculty of Health Sciences, Simon Fraser University, Canada.
Marc G RomneyDivision of Medical Microbiology and Virology, St. Paul's Hospital, Canada.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Canada.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Canada.
Simon Fraser University · CAUniversity of British Columbia · CAAIDS Vancouver · CASt. Paul's Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThird COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.

methodsWe measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines.

resultsFollowing two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses.

conclusionResults underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.

Identifiers

PMID35018381
PMCPMC8750654
OpenAlexW4205819516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.